Copenhagen Q4: 10 Key Results
The fourth-quarter earnings season on the Copenhagen Stock Exchange took place against a backdrop of a significant market decline, with the OMXC25 index falling by 8.81%. The results were characterized by mixed signals: several companies' reports were distorted by large one-off factors, making it difficult to assess underlying performance and leading investors to focus more on future guidance.
Results: The company reported a record 301% jump in net profit, but operating profit growth remained stable at 19.4%. Reasons: The profit was mainly inflated by a one-off revaluation of an investment. The core business continued to be supported by strong palm oil prices. Market Reaction: The stock reacted modestly to the news and has fallen 1.3% since the results were released, reflecting the market's caution regarding one-off gains.
Results: Operating profit grew by 9.4%, but the stock fell. Reasons: Growth was driven by increased sales volumes in Western Europe. The company also provided strong growth guidance for 2026 (6-10%), but this failed to lift investor sentiment. Market Reaction: The stock has fallen 4.5% since the results were released, suggesting possible profit-taking or that expectations were even higher.
Results: A reported loss due to merger costs, but the bank's net revenue grew by a strong 25.5% at the same time. Reasons: The result was impacted by a one-off cost of DKK 942 million related to a merger. However, investors focused on the strength of the core business and the positive guidance for 2026. Market Reaction: The stock initially jumped 5.0% but has since declined and is now 1.0% below its pre-results level.
Results: Operating profit fell by 20.0%, and the 2026 guidance was disappointing. Reasons: Profitability was pressured by higher raw material costs and depreciation related to investments. However, the story took a positive turn when the company announced its largest-ever contract, worth €2.2 billion, shortly after the results. Market Reaction: The stock initially reacted positively to the results (+4.9%) but has since fallen and is now 0.9% below its pre-results level.
Results: Operating profit growth slowed significantly to 6.3%, compared to 14.8% in the previous quarter. Reasons: Although sales revenue grew, profitability was hampered by faster-growing production costs, raising concerns about margins. Market Reaction: The market reacted negatively. The stock fell 4.1% on the day of the results and has continued to decline, now trading 10.0% lower than before the announcement.
Results: The company showed an impressive acceleration in operating profit growth to 88.8%. Reasons: Growth was driven by strong sales of allergy tablets (SLIT) and the successful launch of the new drug neffy®. The 2026 guidance was also strong. Market Reaction: Surprisingly muted. The stock initially fell 2.5% and has remained near that level, indicating that many of the positive expectations may have already been priced in.
Results: Operating profit fell sharply, turning into a loss of DKK 64 million. Reasons: The decline was due to increased costs associated with the acquisition of an unprofitable Turkish company. However, management presented a restructuring plan and optimistic guidance for 2026. Market Reaction: The market ignored the weak result and focused on the future. The stock rose 6.1% on the day of the results and has held most of that gain, trading 5.0% higher than before the announcement.
Results: The biotech company's operating loss increased by 27.9%. Reasons: The loss was widened, as expected, by investments in the development of obesity drugs, which is the company's main strategic focus. Market Reaction: Investors reacted negatively to the rising costs. The stock fell 3.4% on the day of the results and has since declined further, down a total of 10.1%.
Results: Operating profit grew by 47.7%, but net profit was negative. Reasons: Operating profit was supported by successful cost cuts and a one-off property sale. This indicates that the company's restructuring is bearing fruit. Market Reaction: The stock fell 3.6% on the results and has continued to decline. This suggests possible profit-taking, as the stock had experienced a strong rally before the announcement.
Results: Operating profit plummeted by 81.3%, while sales revenue grew by a strong 14.6%. Reasons: The profit decline was caused by large one-off investments in product development and an acquisition. However, underlying sales growth remained strong. Market Reaction: The stock initially reacted positively (+4.4%) but has since fallen and is now 5.6% below its pre-results level, reflecting uncertainty about the large expenses.
Conclusion
Copenhagen's fourth-quarter earnings season was complex and uneven, offering several lessons for investors.
First, one-off factors dominated. The results of several large companies (ALSYDB, UIE, GMAB, FLS) were distorted by significant one-time costs or revenues. This made reading the headlines misleading and required deeper analysis to understand the true state of the underlying business.
Second, future guidance often carried more weight than the past quarter's numbers. DFDS's stock rose on weak results thanks to its restructuring plan, while NKT's weak guidance initially overshadowed its record order intake.
Third, cost pressures persisted. Some industrial and construction companies (PAAL-B, NKT) faced rising costs that squeezed profit margins. This shows that inflationary pressure has not completely disappeared.
In summary, the season reflected the broader market decline. There were few clear winners, but in many cases, negative headlines concealed strong underlying trends or promising future plans. In the next season, it will be crucial to monitor whether companies can deliver on their promises and protect their margins.
RYTM content is for informational purposes only, not financial advice or recommendations. You are solely responsible for your investment decisions. Always consult a professional.